Conference on Retrovirus and Opportunistic Infections (CROI 2020)

CAC progression up in men with HIV on testosterone therapy

Elvira Manzano, 20200610104500

Men with HIV who are on testosterone therapy appear to have an elevated risk for significant coronary artery calcium progression (CAC) vs those who are not on it, according to a study released at CROI 20.

Does a single round of 3HP work for PLWH on ART?

Elvira Manzano, 20200528143000

A once-weekly tuberculosis (TB) prevention regimen of isoniazid 900 mg and rifapentine 900 mg given for 3 months (3HP) resulted in higher treatment completion rates vs isoniazid daily for 6 months (6H) in patients with HIV receiving antiretroviral therapy (ART), a study released at CROI 2020 has shown.

DTG/FTC/TAF a suitable ART regimen in pregnancy

Roshini Claire Anthony, 20200514140001

The combination of dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide fumarate (TAF) has superior virologic efficacy and safety compared with an efavirenz (EFV)/FTC/tenofovir disoproxil fumarate (TDF) combination in pregnant women living with HIV (WLHIV), results of the IMPAACT 2010/VESTED* trial showed.

Second patient cured of HIV through stem cell transplant

Pearl Toh, 20200513190000

The second HIV patient to successfully undergo stem cell transplantation is still in remission, a good 30 months after stopping antiretroviral therapy (ART) — raising hope that curing HIV is a possibility.

Overall, not comorbidity-free, life expectancy gap narrowed between HIV+, HIV- persons

Roshini Claire Anthony, 20200424140003

The gap in overall life expectancy between people with HIV (PWH) and those without HIV has narrowed over time, particularly among optimally treated PWH. However, PWH still have fewer comorbidity-free years than those without HIV, according to a study presented at CROI 2020.

Short-course sofosbuvir-velpatasvir inferior to standard course for HCV

Roshini Claire Anthony, 20200416140002

A six-week course of sofosbuvir-velpatasvir is insufficient to achieve virological response among patients with recent hepatitis C virus (HCV) infection, according to the phase IV REACT* trial.

Bone mass higher in HIV+ children on efavirenz than lopinavir/ritonavir

Audrey Abella, 20200413100000

Children with HIV (HIV+) who switched to efavirenz had higher bone mass even after 4 years of switching compared with those who remained on an antiretroviral therapy (ART) regimen comprising lopinavir and ritonavir, according to data presented at CROI 2020.

TB prevalence high in MDR-TB household contacts

Roshini Claire Anthony, 20200408140012

A high number of household contacts (HHCs) of adults with multi-drug-resistant tuberculosis (MDR-TB) will develop the infection, according to the PHOENIx Feasibility study presented at CROI 2020.

FLAIR confirms therapeutic potential of cabotegravir-rilpivirine in HIV

Audrey Abella, 20200401100000

A long-acting (LA) injectable therapeutic regimen comprising the integrase strand-transfer inhibitor cabotegravir and the nonnucleoside reverse-transcriptase inhibitor rilpivirine shows therapeutic potential over an oral antiretroviral therapy (ART) regimen in adults with HIV-1, according to the week 96 results of the phase III FLAIR* trial.

Every-2-month cabotegravir + rilpivirine feasible for people with HIV

Every-2-month cabotegravir + rilpivirine feasible for HIV treatment

Pearl Toh, 20200327183000

Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.